Top Markets
Coin of the day
Redx Pharma Plc Redx Pharma Plc

Redx Pharma Plc

REDX
株式のランク #38811
Redx Pharma Plc, established in the United Kingdom in 2010 and headquartered in... Redx Pharma Plc, established in the United Kingdom in 2010 and headquartered in Macclesfield, concentrates its efforts on the discovery, early-stage preclinical development, and licensing of innovative small molecule drugs. The company primarily targets significant unmet medical needs in the therapeutic areas of oncology and fibrosis. Within its oncology portfolio, Redx is progressing RXC004, a porcupine inhibitor currently undergoing Phase II clinical evaluation for treating cancers driven by Wnt-ligands. Additionally, it maintains a research collaboration with Jazz Pharmaceuticals plc, aiming to identify and advance new drug candidates for two specific cancer pathways: the Ras/Raf/MAP kinase pathway. For fibrotic conditions, Redx Pharma is developing several compounds, including RXC007, an oral selective ROCK2 inhibitor intended for the treatment of various fibrotic diseases. Its pipeline also features a gastrointestinal-targeted ROCK inhibitor specifically designed to address fibrosis associated with Crohn's disease, along with a discoidin domain receptors (DDRs) inhibitor for a range of fibrotic disorders. Furthermore, the company is developing RXC006, another porcupine inhibitor, focused on combating fibrotic illnesses such as idiopathic pulmonary fibrosis.
株価
$0.20410523
最終同期: 2024-04-30
時価総額
$793.94K
変化(1日)
42.54%
変化(1年)
0.00%
GB
取引 Redx Pharma Plc (REDX)

カテゴリー

Redx Pharma Plc(REDX)の配当履歴
Redx Pharma Plc(証券コード:REDX)は合計で0回の配当を行いました。
すべての配当の合計(株式分割調整済み)は:0.00
配当利回り(TTM):0
2026から2026までのRedx Pharma Plc(REDX)の配当履歴
年間配当支払い
配当(株式分割調整済み) 変化
提供された日付のデータは十分ではありません。
すべての配当支払いの一覧
配当 変化
提供された日付のデータは十分ではありません。
同業他社や競合企業の配当履歴